Cardiotoxicity in Non-Metastatic Lung Cancer Patients Treated with Radiation Therapy, CLARITY Cohort Study

Inclusion Criteria

• >= 18 years of age
• Patient must have histologically confirmed or clinically diagnosed non-small cell lung cancer (NSCLC) where the plan is for definitive treatment that includes radiation
• Able to give written informed consent

Exclusion Criteria

• Pregnant or breast-feeding: Due to risks and potential harm to the unborn fetus, a negative pregnancy test within 10 days prior to the baseline visit is required in women with child-bearing potential. Due to potential nursing infant harm, women who are currently breast-feeding are not eligible for this study. Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea or have had a surgical bilateral oophorectomy or tubal ligation
• Prior thoracic radiotherapy that would result in overlap of radiation therapy in the heart
• Prior treatment with anthracyclines
• Eastern Cooperative Oncology Group (ECOG) performance status > 2
• Vulnerable patients, including pregnant women and prisoners
• Absolute contraindication to rest/vasodilator stress PET/CT, including: * Known Mobitz Type II atrioventricular (AV) block, third-degree AV block, or sick sinus syndrome, without a pacemaker * Systolic blood pressure < 90 mmHg (average over the month prior to enrollment) * Known hypersensitivity to Regadenson or adenosine (hypersensitivity to one of the two agents is not necessarily exclusionary, but will be reviewed with nuclear cardiology locally or at the Core Lab) * Profound sinus bradycardia (heart rate < 40 beats per minute [bpm]) (average over the month prior to enrollment)